Ivonescimab shows 34% intracranial response in NSCLC brain mets; median PFS 19.3 months

Summit Therapeutics Inc.

Intracranial response rate 34% (23% complete) in NSCLC patients with brain metastases; median PFS 19.3 months.
Ivonescimab + chemo in 1L squamous NSCLC: median PFS 11.1 months; non-squamous: 13.3 months; OS not reached at 22.1 months.
No intracranial bleeding observed across cohorts; safety profile manageable with 11.1% discontinuation in squamous group.
Two Phase III trials ongoing: HARMONi (EGFR-mutant post-TKI) and HARMONi-3 (1L squamous NSCLC).
Data presented at ELCC 2024; posters available on company website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.